Na Uy -
Tiếng Na Uy -
Statens legemiddelverk
solu-medrol 1 g
orifarm as - metylprednisolonnatriumsuksinat - pulver og væske til injeksjonsvæske, oppløsning - 1 g
Na Uy -
Tiếng Na Uy -
Statens legemiddelverk
septocaine 40 mg/ ml / 5 mikrog/ ml
septodont - artikainhydroklorid / adrenalintartrat - injeksjonsvæske, oppløsning - 40 mg/ ml / 5 mikrog/ ml
Na Uy -
Tiếng Na Uy -
Statens legemiddelverk
septocaine forte 40 mg/ ml / 10 mikrog/ ml
septodont - artikainhydroklorid / adrenalintartrat - injeksjonsvæske, oppløsning - 40 mg/ ml / 10 mikrog/ ml
Liên Minh Châu Âu -
Tiếng Na Uy -
EMA (European Medicines Agency)
kineret
swedish orphan biovitrum ab (publ) - anakinra - arthritis, rheumatoid; covid-19 virus infection - immunsuppressive - rheumatoid arthritis (ra)kineret is indicated in adults for the treatment of the signs and symptoms of ra in combination with methotrexate, with an inadequate response to methotrexate alone. covid-19kineret is indicated for the treatment of coronavirus disease 2019 (covid-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (supar) ≥ 6 ng/ml. periodic fever syndromeskineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:cryopyrin-associated periodic syndromes (caps)kineret is indicated for the treatment of caps, including:neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca)muckle-wells syndrome (mws)familial cold autoinflammatory syndrome (fcas)familial mediterranean fever (fmf)kineret is indicated for the treatment of familial mediterranean fever (fmf). kineret bør gis i kombinasjon med colchicine, hvis det er aktuelt. still’s diseasekineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of still’s disease, including systemic juvenile idiopathic arthritis (sjia) and adult-onset still’s disease (aosd), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (nsaids) or glucocorticoids. kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (dmards).
Na Uy -
Tiếng Na Uy -
Statens legemiddelverk
brevibloc 10 mg/ ml
baxter medical ab - esmololhydroklorid - infusjonsvæske, oppløsning - 10 mg/ ml
Na Uy -
Tiếng Na Uy -
Statens legemiddelverk
brevibloc 10 mg/ ml
baxter medical ab - esmololhydroklorid - injeksjonsvæske, oppløsning - 10 mg/ ml